RNA transfection

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

Thursday, October 14, 2021 - 9:06pm

Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H in an effort to reduce synthesis of SOD1 protein production.

Key Points: 
  • Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H in an effort to reduce synthesis of SOD1 protein production.
  • Biogen licensed tofersen from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) under a collaborative development and license agreement.
  • Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
  • To learn more, please visit www.biogen.com and follow us on social media Twitter , LinkedIn , Facebook , YouTube .

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

Thursday, October 14, 2021 - 9:54pm

Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.

Key Points: 
  • Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.
  • An estimated 10% or more of adults with AAT deficiency develop clinically meaningful liver disease.2,3 People with AAT deficiency may also develop lung disease, including emphysema.
  • Dicerna is currently investigating the use of belcesiran for the treatment of AATLD in the SHINE clinical development program.
  • The Liver Meeting is a registered trademark of the American Association for the Study of Liver Diseases.

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Thursday, October 14, 2021 - 6:35pm

Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.

Key Points: 
  • Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.
  • The companys flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.
  • Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services.
  • The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery.

Versatope Expands Scientific Advisory Board with Dr. Drew Weissman and Board of Directors with Dr. James Kuo and Jeremy Gowler

Thursday, October 14, 2021 - 3:18pm

LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.

Key Points: 
  • LOWELL, Mass., Oct. 14, 2021 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics,announced today that Dr. Drew Weissman, a leading mRNA vaccine expert, joined their Scientific Advisory Board.
  • Separately, Dr. James Kuo and Jeremy Gowler joined the company's Board of Directors to diversify their pipeline and expand their business development activities.
  • Versatope is developing first-in-class vaccines and immuno-therapeutics for infectious and chronic diseases by using their proprietary recombinant outer membrane vesicle (rOMV) platform.
  • Dr. Drew Weissman, MD, PhD,is the Roberts Family Professor of Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania.

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

Thursday, October 14, 2021 - 2:20pm

Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.

Key Points: 
  • Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.
  • This emulsome nano-carrier, when loaded with bio-active agents (such as poorly water-soluble pharmaceuticals and genetic materials, including DNA and RNA), may increase their solubility and bioavailability.
  • Avalon is actively exploring the practical uses of SLET, including targeted drug delivery, vaccine development, diagnostic devices, and cellular therapeutic applications.
  • The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy.

Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021

Thursday, October 14, 2021 - 1:00pm

ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results, and provide a corporate update.

Key Points: 
  • ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results, and provide a corporate update.
  • To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 9177025.
  • A webcast of the call will also be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine

Thursday, October 14, 2021 - 12:00pm

CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.
  • Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential futureOEC development candidates.
  • "Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics.
  • Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform.

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Thursday, October 14, 2021 - 12:00pm

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today.

Key Points: 
  • ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today.
  • His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.
  • Prior to CRISPR Therapeutics, Mr. Smith was the Chief Financial Officer & Corporate Strategy of Translate Bio, a leading mRNA company that was recently acquired by Sanofi for $3.2B.
  • CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG.

CRB Marks Five Years, Nearly 100 Successful Life Sciences Projects In Europe

Thursday, October 14, 2021 - 5:01am

CRB provides successful integrated project delivery for clients demanding high-quality solutions, on time and within budget.

Key Points: 
  • CRB provides successful integrated project delivery for clients demanding high-quality solutions, on time and within budget.
  • "Our growth in Europe reflects CRB's commitment to the continent as a critical part of the global biopharma value chain.
  • "Our teams excel at developing projects ranging from small research facilities tocomplex construction projects, and at scaling emerging life sciences technologies to bring therapies to market, faster."
  • CRB is a leading provider of sustainable engineering, architecture, construction, and consulting solutions to the food and beverage and life sciences industries.

CRB Marks Five Years, Nearly 100 Successful Life Sciences Projects In Europe

Thursday, October 14, 2021 - 5:01am

CRB provides successful integrated project delivery for clients demanding high-quality solutions, on time and within budget.

Key Points: 
  • CRB provides successful integrated project delivery for clients demanding high-quality solutions, on time and within budget.
  • "Our growth in Europe reflects CRB's commitment to the continent as a critical part of the global biopharma value chain.
  • "Our teams excel at developing projects ranging from small research facilities tocomplex construction projects, and at scaling emerging life sciences technologies to bring therapies to market, faster."
  • CRB is a leading provider of sustainable engineering, architecture, construction, and consulting solutions to the food and beverage and life sciences industries.